March 1, 2017 10:21 AM EST

Celgene, Agios beat a short path to an FDA decision on AML drug

Arsalan Arif

Founder

Celgene and Agios are flooring the gas pedal in their race to gain a very quick — and early — approval for enasidenib (AG-221/CC-90007), their experimental …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Celgene, Agios beat a short path to an FDA decision on AML drug

Arsalan Arif

Founder

Sign up to read this article for free.

A look at biotech's year of the megaround

Regeneron buys London-based ocular biotech

Neumora's major depression drug flunks first of three Phase 3 trials

Pfizer ends work on Sangamo's hemophilia gene therapy, crushing biotech's hopes

Pennsylvania Blue Cross insurer restricts coverage of medicines granted FDA accelerated approval

Roche circles back to China biotech with $80M deal for lung cancer ADC

Cel­gene, Agios beat a short path to an FDA de­ci­sion on AML drug

Arsalan Arif

Founder

Sign up to read this article for free.

more like this

A look at biotech's year of the megaround

Re­gen­eron buys Lon­don-based oc­u­lar biotech

Neu­mora's ma­jor de­pres­sion drug flunks first of three Phase 3 tri­als

Pfiz­er ends work on Sang­amo's he­mo­phil­ia gene ther­a­py, crush­ing biotech's hopes

Penn­syl­va­nia Blue Cross in­sur­er re­stricts cov­er­age of med­i­cines grant­ed FDA ac­cel­er­at­ed ap­proval

Roche cir­cles back to Chi­na biotech with $80M deal for lung can­cer ADC

Celgene, Agios beat a short path to an FDA decision on AML drug

Regeneron buys London-based ocular biotech

Neumora's major depression drug flunks first of three Phase 3 trials

Pfizer ends work on Sangamo's hemophilia gene therapy, crushing biotech's hopes

Pennsylvania Blue Cross insurer restricts coverage of medicines granted FDA accelerated approval

Roche circles back to China biotech with $80M deal for lung cancer ADC